CD8A and neoplasm: In the MC38 TB mice at the end of the off ceralasertib monotherapy treatment period (7 days-on/7days-off), ceralasertib treatment slightly reduced CD8+ T-cells in the tumor and spleen (Supplementary Fig. 6A) and showed minimal effects on the effector or memory CD4+ or CD8+ T-cells similar to the CT26 model, although T-cell numbers were low in MC38 tumors (Supplementary Fig. 6B, C).